Compare NVR Inc. Common Stock (NVR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NVR Inc. Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? NVR Inc. Common Stock trades at $5,750 (market cap $15.45B), while Recursion Pharmaceuticals Inc trades at $3.67 (market cap $2.08B). The key difference: NVR Inc. Common Stock is far larger — about 7.4× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, NVR Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NVR Inc. Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NVR | RXRX | |
|---|---|---|
Market Cap | $15.45B | $2.08B |
Volume | 53,419 | 19,700,033 |
Sector | Consumer Cyclical | Health |
52-Week High | $8.10K | $6.79 |
52-Week Low | $5.56K | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $15.36B | $1.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
